Jeremy Goldberg

President, JPG Healthcare LLC
Operating Partner, Arsenal Capital Partners

Jeremy P. Goldberg is an Advisor to Torreya Partners (www.torreya.com), a leading boutique advisory firm based in New York and London that provides strategic advice and assistance with Mergers & Acquisitions, Partnering and, as well as Advises several $1 billion + private equity funds, including Riverside Partners, DRI Capital, and serves as an Operating Partner for Arsenal Capital Partners, and on several private company board of directors. He has over 25 years of experience, mainly focused on investing and business development in the pharmaceutical and healthcare industries. He has been an operating executive in a $1 billion + sales pharmaceutical company, a partner in a venture capital fund, and an entrepreneurial founder of several companies that were later acquired.

Mr. Goldberg served as Managing Director, Corporate Development for Endo Pharmaceuticals (NASDAQ: ENDP), a leading pain therapeutics company, from 2003-2008. In this position, Mr. Goldberg was responsible for Endo’s overall corporate development activities, including structuring, negotiating and closing transactions such as the acquisitions of companies, products and product lines. Prior to Endo, he was a founding partner of ProQuest Investments from 1997-2002, the first cancer-focused venture capital fund, where he and partners raised over $250 MM in Funds I, II to acquire positions in biotechnology, specialty pharmaceutical, and medical device companies. Representative investments or deals sourced include Conforma Therapeutics (acquired by Biogen IDEC), Threshold Pharmaceuticals, and Pharmion (acquired by Celgene). Prior operating experience includes roles as founding CEO or founder of three biotechnology companies that were acquired or taken public, including Versicor (Vicuron), a Sepracor spin-out later acquired by Pfizer for $1.9 billion, as well as operating positions at SmithKline (now Glaxo SmithKline) and Becton Dickinson.

Mr. Goldberg is magna cum laude graduate of Harvard College and Harvard Business School. He serves on the Visiting Committee for the Lank Center at Dana Farber Cancer Institute and has been a member of the board of the International Biomedical Research Alliance since 2007 as well as on the board of private companies Cell Signaling Technology, Dominion Diagnostics. He has been an invited speaker at the University of Pennsylvania Wharton/Windhover program for Pharmaceutical executives, Harvard Business School, and served as moderator for over 10 years for Communitech’s Cancer Progress conference.